Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation

Bone

Volumn 50, Issue 2, 2012, Pages 467-476

  Weivoda, Megan M ^a   Hohl, Raymond J ^a,b  

^a Department of Pharmacology ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Adipogenesis; Geranylgeranyl pyrophosphate; Osteoblast

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GERANYLGERANYL PYROPHOSPHATE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HOMEOSTASIS; MALE; METABOLIC REGULATION; MINERALIZATION; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT; STROMA CELL; TRANSCRIPTION INITIATION;

ADIPOGENESIS; ANIMALS; CELL LINE; MICE; OSTEOBLASTS; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; PPAR GAMMA; PRENYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, INSULIN; SKULL; TRANSCRIPTION, GENETIC;

EID: 84855879737     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.09.056     Document Type: Article

References (44)

1. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
2. Ruiz-Gaspa S., Nogues X., Enjuanes A., Monllau J.C., Blanch J., Carreras R., et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 2007, 101:1430-1438.
3. Chen P., Sun J.S., Tsuang Y.H., Chen M.H., Weng P.W., Lin F.H. Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 2010, 30:191-199.
4. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001, 280:874-877.
5. Maeda T., Kawane T., Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003, 144:681-692.
6. Maeda T., Matsunuma A., Kurahashi I., Yanagawa T., Yoshida H., Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 2004, 92:458-471.
7. Li X., Cui Q., Kao C., Wang G.J., Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 2003, 33:652-659.
8. Ohnaka K., Shimoda S., Nawata H., Shimokawa H., Kaibuchi K., Iwamoto Y., et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001, 287:337-342.
9. Pagkalos J.C.J., Kang Y., Heliotis M., Tsiridis E., Mantalaris A. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 2010, 25:2470-2478.
10. Chuengsamarn S., Rattanamongkoulgul S., Suwanwalaikorn S., Wattanasirichaigoon S., Kaufman L. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 2010, 46:1011-1015.
11. Edwards C., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355:2218-2219.
12. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
13. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977, 77:31-36.
14. Holstein S., Hohl R.J. Isoprenoids: remarkable diversity of form and function. Lipids 2004, 39:293-309.
15. Casey P., Seabra M.C. Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292.
16. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
17. Goldstein J., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
18. Weivoda M., Hohl R.J. The effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology 2011, 152:3113-3122.
19. Weivoda M., Hohl R.J. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J Cell Biochem 2011, 112:1506-1513.
20. Yoshida T., Asanuma M., Grossmann L., Fuse M., Shibata T., Yonekawa T., et al. Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3-E1. FEBS Lett 2006, 580:5203-5207.
21. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastic program. Cell Mol Life Sci 2009, 66:236-253.
22. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312.
23. Nuttall M.E., Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:290-294.
24. Lecka-Czernik B., Rosen C.J., Kawai M. Skeletal aging and the adipocyte program: new insights from an "old" molecule. Cell Cycle 2010, 9:3648-3654.
25. de Paula F., Horowitz M.C., Rosen C.J. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 2010, 26:622-630.
26. Kawai M., Rosen C.J. PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010, 6:629-636.
27. Lecka-Czernik B., Gubrij I., Moerman E.J., Kajkenova O., Lipschitz D.A., Manolagas S.C., et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999, 74:357-371.
28. Song C., Guo Z., Ma Q., Chen Z., Liu Z., Jia H., et al. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 2003, 308:458-462.
29. Vicent D., Maratos-Flier E., Kahn C.R. The branch point enzyme of the mevalonate pathway for protein prenylation is overexpressed in the ob/ob mouse and induced by adipogenesis. Mol Cell Biol 2000, 20:2158-2166.
30. Tong H., Holstein S.A., Hohl R.J. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 2005, 336:51-59.
31. Bordier C. Phase separation of integral membrane proteins in triton X-114 solution. J Biol Chem 1981, 256:1604-1607.
32. Gregory C., Gunn W.G., Peister A., Prockop D.J. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 2004, 329:77-84.
33. Pittenger M., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
34. Shull L., Wiemer A.J., Hohl R.J., Wiemer D.F. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem 2006, 14:4130-4136.
35. Wiemer A.J., Tong H., Swanson K.M., Hohl R.J. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun 2007, 353:921-925.
36. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
37. Fulzele K., Riddle R.C., DiGirolamo D.J., Cao X., Wan C., Chen D., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
38. Chen H., Chen C.H., Chuang N.N. Differential effects of prenyl pyrophosphates on the phosphatase activity of phosphotyrosyl protein phosphatase. J Exp Zool A Comp Exp Biol 2004, 301:307-316.
39. Shen N., Yu X., Pan F.Y., Gao X., Xue B., Li C.J. An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism. J Biol Chem 2011, 286:14508-14515.
40. Takase H., Yano S., Yamaguchi T., Kanazawa I., Hayashi K., Yamamoto M., et al. Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm Metab Res 2009, 41:861-865.
41. Moerman E., Teng K., Lipschitz D.A., Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379-389.
42. Leesnitzer L., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., et al. Functional consequences of cysteine modification in the ligand binding sites of perxoisome proliferator activated receptors by GW9662. Biochemistry 2002, 41:6640-6650.
43. Julien S., Tremblay M.L. Insulin Receptor PTP:PTP1B. Handbook of Cell Signaling 2010, 811-815. Elsevier.
44. Choi H., Choi J.Y., Cho S.W., Kang D., Han K.O., Kim S.W., et al. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J 2010, 51:231-238.